Method for the production of immunoadsorbers Claim 14 (amended). according to Claim 1, wherein antibodies aimed against C3a and/or C5a and LPS and, if need be, against further sepsis mediators are covalently or adsorptively coupled to carrier materials of organic or synthetic polymers.

Please cancel claims 16 and 17.

REMARKS

This Preliminary Amendment is being filed to place the claims into conventional format, and to eliminate improper multiple dependency.

Favorable action is respectfully solicited.

ADDITIONAL FEE

Please charge any insufficiency of fees, or credit any excess, to Deposit Account No. 14-1263.

Respectfully submitted,

NORRIS, MICLAUGHLINA MARCUS

Bruce &. Londa Reg. No. 33,531

220 East 42nd Street - 30th Floor New York, New York 10017 (212) 808-0700

I hereby certify that this paper is being deposited with the United States Postal Service as Express Mail, Label No. EL867734725US to: BOX PCT, The Hon. Commissioner of Patents, Washington, D.C. 20231 on September 20, 2001

Norris McLaughlin & Marcus, 4


Date:

4)

ijŢ

1.1 (1)

e Pri



Claim 4 (amended). Immunoadsorber according to [Claims 1 to 3] <u>Claim 1</u>, wherein further antibodies against sepsis mediators are contained as a function of the state of the dysregulation.

Claim 5 (amended). Immunoadsorber according to [Claims 1 to 4] Claim 1, wherein these antibodies are aimed against TNF, IL1, IL6, IL8 and/or IL10.

Claim 11 (amended). Immunoadsorber according to [Claims 1 to 10] <u>Claim 1</u>, wherein the organic or synthetic carrier material comprises membranes of particles of polystyrenes, carbohydrates such as cellulose or agarose derivates, or acrylates.

Claim 14 (amended). Method for the production of immunoadsorbers according to [Claims 1 to 13] Claim 1, wherein antibodies aimed against C3a and/or C5a and LPS and, if need be, against further sepsis mediators are covalently or adsorptively coupled to carrier materials of organic or synthetic polymers.